Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Altmann

Showing results (371-380 of 383) with videos related to

Pageof 39
Sort By:
Cell Reports. Medicine|April 27, 2022
Rapid synchronous type 1 IFN and virus-specific T cell responses characterize first wave non-severe SARS-CoV-2 infectionsAneesh Chandran, Joshua Rosenheim, Gayathri Nageswaran, et al.
The Lancet. Gastroenterology & Hepatology|February 6, 2022
COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control studyJames L Alexander, Nicholas A Kennedy, Hajir Ibraheim, et al.
Iscience|June 5, 2023
Large clones of pre-existing T cells drive early immunity against SARS-COV-2 and LCMV infectionMartina Milighetti, Yanchun Peng, Cedric Tan, et al.
Nature Communications|March 17, 2022
Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumabSimeng Lin, Nicholas A Kennedy, Aamir Saifuddin, et al.
Journal of Crohn'S & Colitis|November 9, 2023
Antibody Responses to Influenza Vaccination are Diminished in Patients With Inflammatory Bowel Disease on Infliximab or TofacitinibZhigang Liu, James L Alexander, Kai Yee Eng, et al.
The Lancet. Gastroenterology & Hepatology|September 11, 2022
COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control studyJames L Alexander, Zhigang Liu, Diana Muñoz Sandoval, et al.
Nature|November 10, 2021
Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2Leo Swadling, Mariana O Diniz, Nathalie M Schmidt, et al.
Scientific Reports|September 27, 2022
Serum biomarkers associated with SARS-CoV-2 severityFabiani de Morais Batista, Marco Antonio Moreira Puga, Patricia Vieira da Silva, et al.
BMC Infectious Diseases|July 28, 2023
Multicenter study of the natural history and therapeutic responses of patients with chikungunya, focusing on acute and chronic musculoskeletal manifestations - a study protocol from the clinical and applied research in Chikungunya (REPLICK network)Giselle da Silva Duarte, Alexandra D Jones, Luciano Pamplona de Goes Cavalcanti, et al.
Eclinicalmedicine|October 16, 2023
Neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 and wild-type virus in patients with inflammatory bowel disease following three doses of COVID-19 vaccine (VIP): a prospective, multicentre, cohort studyZhigang Liu, James L Alexander, Kaixing Le, et al.
Pageof 39

Showing results (371-380 of 383) with videos related to

Sort By:
Pageof 39
Cell Reports. Medicine|April 27, 2022
Rapid synchronous type 1 IFN and virus-specific T cell responses characterize first wave non-severe SARS-CoV-2 infectionsAneesh Chandran, Joshua Rosenheim, Gayathri Nageswaran, et al.
The Lancet. Gastroenterology & Hepatology|February 6, 2022
COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control studyJames L Alexander, Nicholas A Kennedy, Hajir Ibraheim, et al.
Iscience|June 5, 2023
Large clones of pre-existing T cells drive early immunity against SARS-COV-2 and LCMV infectionMartina Milighetti, Yanchun Peng, Cedric Tan, et al.
Nature Communications|March 17, 2022
Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumabSimeng Lin, Nicholas A Kennedy, Aamir Saifuddin, et al.
Journal of Crohn'S & Colitis|November 9, 2023
Antibody Responses to Influenza Vaccination are Diminished in Patients With Inflammatory Bowel Disease on Infliximab or TofacitinibZhigang Liu, James L Alexander, Kai Yee Eng, et al.
The Lancet. Gastroenterology & Hepatology|September 11, 2022
COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control studyJames L Alexander, Zhigang Liu, Diana Muñoz Sandoval, et al.
Nature|November 10, 2021
Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2Leo Swadling, Mariana O Diniz, Nathalie M Schmidt, et al.
Scientific Reports|September 27, 2022
Serum biomarkers associated with SARS-CoV-2 severityFabiani de Morais Batista, Marco Antonio Moreira Puga, Patricia Vieira da Silva, et al.
BMC Infectious Diseases|July 28, 2023
Multicenter study of the natural history and therapeutic responses of patients with chikungunya, focusing on acute and chronic musculoskeletal manifestations - a study protocol from the clinical and applied research in Chikungunya (REPLICK network)Giselle da Silva Duarte, Alexandra D Jones, Luciano Pamplona de Goes Cavalcanti, et al.
Eclinicalmedicine|October 16, 2023
Neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 and wild-type virus in patients with inflammatory bowel disease following three doses of COVID-19 vaccine (VIP): a prospective, multicentre, cohort studyZhigang Liu, James L Alexander, Kaixing Le, et al.
Pageof 39